1. Chugh S, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47. DOI:10.1161/CIRCULATIONAHA.113.005119
2. Dai H, Zhang Q, Much A, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):574-82. DOI:10.1093/ehjqcco/qcaa061
3. Мареев Ю.В., Поляков Д.С., Виноградова Н.Г., и др. ЭПОХА: Эпидемиология фибрилляции предсердий в репрезентативной выборке Европейской части Российской Федерации. Кардиология. 2022;62(4):12-9 [Mareev YuV, Polyakov DS, Vinogradova NG, et al. Epidemiology of atrial fibrillation in a representative sample of the European part of the Russian Federation. Analysis of EPOCH-CHF Study. Kardiologiia. 2022;62(4):12-9 (in Russian)]. DOI:10.18087/cardio.2022.4.n1997
4. Беленков Ю.Н., Шакарьянц Г.А., Хабарова Н.В., Ан Г.В. Антикоагулянтная терапия у пожилых пациентов с фибрилляцией предсердий. Кардиология. 2018;58(10):45-52 [Belenkov YuN, Shakaryants GA, Khabarova NV, An GV. Anticoagulant Therapy in Elderly Patients With Atrial Fibrillation. Kardiologiia. 2018;58(10):45-52 (in Russian)]. DOI:10.18087/cardio.2018.10.10177
5. Бокерия Л.А., Полунина А.Г., Лефтерова Н.П., и др. Фибрилляция предсердий, дилатация левых камер сердца: пусковые механизмы развития когнитивных нарушений у кардиологических пациентов. Креативная кардиология. 2015;9(1):38-45 [Bockeria LA, Polunina AG, Lefterova NF, et al. Atrium fibrillation and enlargement of left heart chambers: pathological mechanisms of cognitive dysfunction in cardiologic patients. Creative Cardiology. 2015;9(1):38-45 (in Russian)]. DOI:10.15275/kreatkard.2015.01.04 
6. Диагностика и лечение фибрилляции предсердий. Клинические рекомендации, 2017. Режим доступа: https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf. Ссылка активна на 26.09.2022 [Diagnostika i lechenie fibrilliatsii predserdii. Klinicheskie rekomendatsii, 2017. Available at: https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf. Accessed: 26.09.2022 (in Russian)]. 
7. Salmasi S, Loewen P, Tandun R, et al. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ Open. 2020;10(4):e034778. DOI:10.1136/bmjopen-2019-034778
8. Jankowska-Polańska B, Lomper K, Alberska L, et al. Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation. J Geriatr Cardiol. 2016;13(7):559. DOI:10.11909/j.issn.1671-5411.2016.07.006
9. Obamiro K, Chalmers L, Lee K, et al. Adherence to oral anticoagulants in atrial fibrillation: An Australian survey. Cardiovasc Pharm Ther. 2018;23:337-43. DOI:10.1177/1074248418770201
10. Seong H, Lee K, Kim B, Son Y. Cognitive impairment is independently associated with non-adherence to antithrombotic therapy in older patients with atrial fibrillation. Int J Environ Res Public Health. 2019;16(15):2698. DOI:10.3390/ijerph16152698
11. Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Thromb Haemost. 2017;117(02):209-18.
DOI:10.1160/TH16-10-0757
12. Cramer J, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7. DOI:10.1111/j.1524-4733.2007.00213.x
13. Tomasdottir M, Friberg L, Hijazi Z, et al. Risk of ischemic stroke and utility of CHA2DS2-VASc score in women and men with atrial fibrillation. Clin Cardiol. 2019;42(10):1003-9. DOI:10.1002/clc.23257
14. Lip G, Laroche C, Popescu M, et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. EP Europace. 2015;17(12):1777-86. DOI:10.1093/europace/euv269
15. Thompson L, Maddox T, Lei L, et al. Sex differences in the use of oral anticoagulants for atrial fibrillation: a report from the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry. J Am Heart Assoc. 2017;6(7):e005801. DOI:10.1161/JAHA.117.005801
16. Eckman M, Wise R, Leonard A, et al. Racial and sex differences in optimizing anticoagulation therapy for patients with atrial fibrillation. American Heart Journal Plus: Cardiology Research and Practice. 2022;18:100170. DOI:10.1016/j.ahjo.2022.100170
17. Charlton A, Vidal X, Sabaté M, et al. Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation. J Manag Care Specy Pharm. 2021;27(9):1210-20. DOI:10.18553/jmcp.2021.27.9.1210
18. Bartolazzi F, Ribeiro A, de Sousa W, et al. Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross-sectional study. J Thromb Thrombolysis. 2021;52(4):1074-80. DOI:10.1007/s11239-021-02432-4
19. Ferguson C, Inglis S, Newton P, et al. Barriers and enablers to adherence to anticoagulation in heart failure with atrial fibrillation: patient and provider perspectives. J Clin Nurs. 2017;26(23-24):4325-34. DOI:10.1111/jocn.13759
20. Cabellos-Garcia A, Martinez-Sabater A, Castro-Sanchez E, et al. Relation between health literacy, self-care and adherence to treatment with oral anticoagulants in adults: a narrative systematic review. BMC Public Health. 2018;18(1):1-12. DOI:10.1186/s12889-018-6070-9
21. Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary nonadherence to chronic disease medications: a meta-analysis. Patient Prefer Adherence. 2018;12:721. DOI:10.2147/PPA.S161151
22. Mandalenakis Z, Von Koch L, Eriksson H, et al. The risk of atrial fibrillation in the general male population: a lifetime follow-up of 50-year-old men. Europace. 2015;17(7):1018-22. DOI:10.1093/europace/euv036
23. Friberg L, Rosenqvist M, Lip G. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-10. DOI:10.1093/eurheartj/ehr488
24. LaMori J, Mody S, Gross H, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53-62. DOI:10.1177/17539447124641
25. Деменко Т.Н., Чумакова Г.А., Чугунова Ю.В. Особенности когнитивной функции у пациентов с фибрилляцией предсердий. Анналы аритмологии. 2015;12(4):215-24 [Demenko TN, Chumakova GA, Chugunova YV. Features of cognitive function in patients with atrial fibrillation. Annaly aritmologii. 2015;12(4):215-24 (in Russian)]. DOI:10.15275/annaritmol.2015.4.3
26. Rohde D, Merriman N, Doyle F, et al. Does cognitive impairment impact adherence? A systematic review and meta-analysis of the association between cognitive impairment and medication non-adherence in stroke. PloS One. 2017;12(12):e0189339. DOI:10.1371/journal.pone.0189339
27. Кобалава Ж.Д., Лазарев П.В., Федорова Д.Н. Когнитивная дисфункция на фоне фибрилляции предсердий: клинико-патогенетические ассоциации, диагностика и профилактика, аспекты применения антикоагулянтной терапии. Кардиология. 2019;59(10):66-77 [Kobalava ZD, Lazarev PV, Fedorova DN. Cognitive Dysfunction at the Background of Atrial Fibrillation: Clinical-Pathological Aspects, Diagnostics and Prevention, Issues of the Use of the Application of Anticoagulant Therapy. Kardiologiia. 2019;59(10):66-77 (in Russian)]. DOI:10.18087/cardio.2019.10.n612
28. Gallagher A, Rietbrock S, Plumb J, Van Staa T. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemostas. 2008;6(9):1500-6. DOI:10.1111/j.1538-7836.2008.03059.x
29. Castellucci L, Shaw J, van der Salm K, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thrombosis Res. 2015;136(4):727-31. DOI:10.1016/j.thromres.2015.07.007
30. Emren S, Şenöz O, Bilgin M, et al. Drug adherence in patients with nonvalvular atrial fibrillation taking non-vitamin K antagonist oral anticoagulants in Turkey: NOAC-TR. Clin Appl Thromb Hemost. 2018;24(3):525-31. DOI:10.1177/1076029617693940
31. Zielinski G, van Rein N, Teichert M, et al. Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: a surveillance study. Res Pract Thromb Haemost. 2020;4(1):141-53. DOI:10.1002/rth2.12261
32. Smith D, Lovell J, Weller C, et al. A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PloS One. 2017;12(2):e0170651. DOI:10.1371/journal.pone.0170651
33. Patel D, McConkey N, Sohaney R, et al. A systematic review of depression and anxiety in patients with atrial fibrillation: the mind-heart link. Cardiovasc Psychiatry Neurol. 2013;2013:159850. DOI:10.1155/2013/159850
34. Polikandrioti M, Koutelekos I, Vasilopoulos G, et al. Anxiety and depression in patients with permanent atrial fibrillation: prevalence and associated factors. Cardiol Res Pract. 2018;2018:7408129. DOI:10.1155/2018/7408129
35. Søgaard M, Skjøth F, Kjældgaard J, et al. Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study. BMJ Open. 2017;7(12):e018209. DOI:10.1136/bmjopen-2017-018209
36. Wu M, Shen L, Wang Q, et al. Anxiety and Depression Prevalence and Risk Factors Among Patients With Cardiovascular Diseases in Post-COVID-19 China. Front Public Health. 2022;9:758874. DOI:10.3389/fpubh.2021.758874
37. Walker E, McGee R, Druss B. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334-41. DOI:10.1001/jamapsychiatry.2014.2502
38. Jayatilleke N, Hayes R, Dutta R, et al. Contributions of specific causes of death to lost life expectancy in severe mental illness. Eur Psychiatry. 2017;43:109-15. DOI:10.1016/j.eurpsy.2017.02.487
39. McGrady A, McGinnis R, Badenhop D, et al. Effects of depression and anxiety on adherence to cardiac rehabilitation. J Cardiopulm Rehabil Prevn. 2009;29(6):358-64. DOI:10.1097/HCR.0b013e3181be7a8f
40. Fenger-Grøn M, Vestergaard C, Frost L, et al. Depression and uptake of oral anticoagulation therapy in patients with atrial fibrillation: a Danish nationwide cohort study. Medical Care. 2020;58(3):216-24. DOI:10.1097/MLR.0000000000001268
41. Reading S, Black M, Singer D, et al. Risk factors for medication non-adherence among atrial fibrillation patients. BMC Cardiovasc Disord. 2019;19(1):38.
DOI:10.1186/s12872-019-1019-1
42. Bauer LK, Caro MA, Beach SR, et al. Effects of depression and anxiety improvement on adherence to medication and health behaviors in recently hospitalized cardiac patients. Am J Cardiol. 2012;109(9):1266-71. DOI:10.1016/j.amjcard.2011.12.017
43. Suzuki T, Shiga T, Omori H, et al. Adherence to medication and characteristics of Japanese patients with non-valvular atrial fibrillation. J Cardiol. 2017;70(3):238-43. DOI:10.1016/j.jjcc.2016.11.009
44. Taylor E, O'Neill M, Hughes L, et al. Examining adherence to medication in patients with atrial fibrillation: the role of medication beliefs, attitudes, and depression. J Cardiovasc Nurs. 2020;35(4):337-46. DOI:10.1097/JCN.0000000000000650
45. Teppo K, Jaakkola J, Airaksinen K, et al. Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study. J Am Heart Assoc. 2022;11(6):e024119. DOI:10.1161/JAHA.121.024119
46. Miyazaki M, Nakashima A, Nakamura Y, et al. Association between medication adherence and illness perceptions in atrial fibrillation patients treated with direct oral anticoagulants: an observational cross-sectional pilot study. PloS One. 2018;13(9):e0204814. DOI:10.1371/journal.pone.0204814
47. Lane D, Meyerhoff J, Rohner U, Lip G. Patients’ perceptions of atrial fibrillation, stroke risk, and oral anticoagulation treatment: An international survey. TH Open. 2018;2(03):e233-41. DOI:10.1055/s-0038-1666803
48. Алёхин А.Н., Трифонова Е.А., Лебедев Д.С., и др. Психологические проблемы в аритмологии (на модели фибрилляции предсердий). Вестник аритмологии. 2011;63:45-54 [Alekhin AN, Trifonova EA, Lebedev DS, et al. Psuchological problems in arrhythmology (on a model of atrial fibrillation). Vestnik aritmologii. 2011;63:45-54 (in Russian)].
49. Streur M, Ratcliffe SJ, Callans D, et al. Atrial fibrillation symptom clusters and associated clinical characteristics and outcomes: A cross-sectional secondary data analysis. Eur J Cardiovasc Nurs. 2018;17(8):707-16. DOI:10.1177/1474515118778445

________________________________________________

1. Chugh S, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47. DOI:10.1161/CIRCULATIONAHA.113.005119
2. Dai H, Zhang Q, Much A, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):574-82. DOI:10.1093/ehjqcco/qcaa061
3. Mareev YuV, Polyakov DS, Vinogradova NG, et al. Epidemiology of atrial fibrillation in a representative sample of the European part of the Russian Federation. Analysis of EPOCH-CHF Study. Kardiologiia. 2022;62(4):12-9 (in Russian). DOI:10.18087/cardio.2022.4.n1997
4. Belenkov YuN, Shakaryants GA, Khabarova NV, An GV. Anticoagulant Therapy in Elderly Patients With Atrial Fibrillation. Kardiologiia. 2018;58(10):45-52 (in Russian). DOI:10.18087/cardio.2018.10.10177
5. Bockeria LA, Polunina AG, Lefterova NF, et al. Atrium fibrillation and enlargement of left heart chambers: pathological mechanisms of cognitive dysfunction in cardiologic patients. Creative Cardiology. 2015;9(1):38-45 (in Russian). DOI:10.15275/kreatkard.2015.01.04 
6. Diagnostika i lechenie fibrilliatsii predserdii. Klinicheskie rekomendatsii, 2017. Available at: https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf. Accessed: 26.09.2022 (in Russian). 
7. Salmasi S, Loewen P, Tandun R, et al. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ Open. 2020;10(4):e034778. DOI:10.1136/bmjopen-2019-034778
8. Jankowska-Polańska B, Lomper K, Alberska L, et al. Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation. J Geriatr Cardiol. 2016;13(7):559. DOI:10.11909/j.issn.1671-5411.2016.07.006
9. Obamiro K, Chalmers L, Lee K, et al. Adherence to oral anticoagulants in atrial fibrillation: An Australian survey. Cardiovasc Pharm Ther. 2018;23:337-43. DOI:10.1177/1074248418770201
10. Seong H, Lee K, Kim B, Son Y. Cognitive impairment is independently associated with non-adherence to antithrombotic therapy in older patients with atrial fibrillation. Int J Environ Res Public Health. 2019;16(15):2698. DOI:10.3390/ijerph16152698
11. Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Thromb Haemost. 2017;117(02):209-18.
DOI:10.1160/TH16-10-0757
12. Cramer J, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7. DOI:10.1111/j.1524-4733.2007.00213.x
13. Tomasdottir M, Friberg L, Hijazi Z, et al. Risk of ischemic stroke and utility of CHA2DS2-VASc score in women and men with atrial fibrillation. Clin Cardiol. 2019;42(10):1003-9. DOI:10.1002/clc.23257
14. Lip G, Laroche C, Popescu M, et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. EP Europace. 2015;17(12):1777-86. DOI:10.1093/europace/euv269
15. Thompson L, Maddox T, Lei L, et al. Sex differences in the use of oral anticoagulants for atrial fibrillation: a report from the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry. J Am Heart Assoc. 2017;6(7):e005801. DOI:10.1161/JAHA.117.005801
16. Eckman M, Wise R, Leonard A, et al. Racial and sex differences in optimizing anticoagulation therapy for patients with atrial fibrillation. American Heart Journal Plus: Cardiology Research and Practice. 2022;18:100170. DOI:10.1016/j.ahjo.2022.100170
17. Charlton A, Vidal X, Sabaté M, et al. Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation. J Manag Care Specy Pharm. 2021;27(9):1210-20. DOI:10.18553/jmcp.2021.27.9.1210
18. Bartolazzi F, Ribeiro A, de Sousa W, et al. Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross-sectional study. J Thromb Thrombolysis. 2021;52(4):1074-80. DOI:10.1007/s11239-021-02432-4
19. Ferguson C, Inglis S, Newton P, et al. Barriers and enablers to adherence to anticoagulation in heart failure with atrial fibrillation: patient and provider perspectives. J Clin Nurs. 2017;26(23-24):4325-34. DOI:10.1111/jocn.13759
20. Cabellos-Garcia A, Martinez-Sabater A, Castro-Sanchez E, et al. Relation between health literacy, self-care and adherence to treatment with oral anticoagulants in adults: a narrative systematic review. BMC Public Health. 2018;18(1):1-12. DOI:10.1186/s12889-018-6070-9
21. Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary nonadherence to chronic disease medications: a meta-analysis. Patient Prefer Adherence. 2018;12:721. DOI:10.2147/PPA.S161151
22. Mandalenakis Z, Von Koch L, Eriksson H, et al. The risk of atrial fibrillation in the general male population: a lifetime follow-up of 50-year-old men. Europace. 2015;17(7):1018-22. DOI:10.1093/europace/euv036
23. Friberg L, Rosenqvist M, Lip G. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-10. DOI:10.1093/eurheartj/ehr488
24. LaMori J, Mody S, Gross H, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53-62. DOI:10.1177/17539447124641
25. Деменко Т.Н., Чумакова Г.А., Чугунова Ю.В. Особенности когнитивной функции у пациентов с фибрилляцией предсердий. Анналы аритмологии. 2015;12(4):215-24 [Demenko TN, Chumakova GA, Chugunova YV. Features of cognitive function in patients with atrial fibrillation. Annaly aritmologii. 2015;12(4):215-24 (in Russian)]. DOI:10.15275/annaritmol.2015.4.3
26. Rohde D, Merriman N, Doyle F, et al. Does cognitive impairment impact adherence? A systematic review and meta-analysis of the association between cognitive impairment and medication non-adherence in stroke. PloS One. 2017;12(12):e0189339. DOI:10.1371/journal.pone.0189339
27. Kobalava ZD, Lazarev PV, Fedorova DN. Cognitive Dysfunction at the Background of Atrial Fibrillation: Clinical-Pathological Aspects, Diagnostics and Prevention, Issues of the Use of the Application of Anticoagulant Therapy. Kardiologiia. 2019;59(10):66-77 (in Russian). DOI:10.18087/cardio.2019.10.n612
28. Gallagher A, Rietbrock S, Plumb J, Van Staa T. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemostas. 2008;6(9):1500-6. DOI:10.1111/j.1538-7836.2008.03059.x
29. Castellucci L, Shaw J, van der Salm K, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thrombosis Res. 2015;136(4):727-31. DOI:10.1016/j.thromres.2015.07.007
30. Emren S, Şenöz O, Bilgin M, et al. Drug adherence in patients with nonvalvular atrial fibrillation taking non-vitamin K antagonist oral anticoagulants in Turkey: NOAC-TR. Clin Appl Thromb Hemost. 2018;24(3):525-31. DOI:10.1177/1076029617693940
31. Zielinski G, van Rein N, Teichert M, et al. Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: a surveillance study. Res Pract Thromb Haemost. 2020;4(1):141-53. DOI:10.1002/rth2.12261
32. Smith D, Lovell J, Weller C, et al. A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PloS One. 2017;12(2):e0170651. DOI:10.1371/journal.pone.0170651
33. Patel D, McConkey N, Sohaney R, et al. A systematic review of depression and anxiety in patients with atrial fibrillation: the mind-heart link. Cardiovasc Psychiatry Neurol. 2013;2013:159850. DOI:10.1155/2013/159850
34. Polikandrioti M, Koutelekos I, Vasilopoulos G, et al. Anxiety and depression in patients with permanent atrial fibrillation: prevalence and associated factors. Cardiol Res Pract. 2018;2018:7408129. DOI:10.1155/2018/7408129
35. Søgaard M, Skjøth F, Kjældgaard J, et al. Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study. BMJ Open. 2017;7(12):e018209. DOI:10.1136/bmjopen-2017-018209
36. Wu M, Shen L, Wang Q, et al. Anxiety and Depression Prevalence and Risk Factors Among Patients With Cardiovascular Diseases in Post-COVID-19 China. Front Public Health. 2022;9:758874. DOI:10.3389/fpubh.2021.758874
37. Walker E, McGee R, Druss B. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334-41. DOI:10.1001/jamapsychiatry.2014.2502
38. Jayatilleke N, Hayes R, Dutta R, et al. Contributions of specific causes of death to lost life expectancy in severe mental illness. Eur Psychiatry. 2017;43:109-15. DOI:10.1016/j.eurpsy.2017.02.487
39. McGrady A, McGinnis R, Badenhop D, et al. Effects of depression and anxiety on adherence to cardiac rehabilitation. J Cardiopulm Rehabil Prevn. 2009;29(6):358-64. DOI:10.1097/HCR.0b013e3181be7a8f
40. Fenger-Grøn M, Vestergaard C, Frost L, et al. Depression and uptake of oral anticoagulation therapy in patients with atrial fibrillation: a Danish nationwide cohort study. Medical Care. 2020;58(3):216-24. DOI:10.1097/MLR.0000000000001268
41. Reading S, Black M, Singer D, et al. Risk factors for medication non-adherence among atrial fibrillation patients. BMC Cardiovasc Disord. 2019;19(1):38.
DOI:10.1186/s12872-019-1019-1
42. Bauer LK, Caro MA, Beach SR, et al. Effects of depression and anxiety improvement on adherence to medication and health behaviors in recently hospitalized cardiac patients. Am J Cardiol. 2012;109(9):1266-71. DOI:10.1016/j.amjcard.2011.12.017
43. Suzuki T, Shiga T, Omori H, et al. Adherence to medication and characteristics of Japanese patients with non-valvular atrial fibrillation. J Cardiol. 2017;70(3):238-43. DOI:10.1016/j.jjcc.2016.11.009
44. Taylor E, O'Neill M, Hughes L, et al. Examining adherence to medication in patients with atrial fibrillation: the role of medication beliefs, attitudes, and depression. J Cardiovasc Nurs. 2020;35(4):337-46. DOI:10.1097/JCN.0000000000000650
45. Teppo K, Jaakkola J, Airaksinen K, et al. Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study. J Am Heart Assoc. 2022;11(6):e024119. DOI:10.1161/JAHA.121.024119
46. Miyazaki M, Nakashima A, Nakamura Y, et al. Association between medication adherence and illness perceptions in atrial fibrillation patients treated with direct oral anticoagulants: an observational cross-sectional pilot study. PloS One. 2018;13(9):e0204814. DOI:10.1371/journal.pone.0204814
47. Lane D, Meyerhoff J, Rohner U, Lip G. Patients’ perceptions of atrial fibrillation, stroke risk, and oral anticoagulation treatment: An international survey. TH Open. 2018;2(03):e233-41. DOI:10.1055/s-0038-1666803
48. Alekhin AN, Trifonova EA, Lebedev DS, et al. Psuchological problems in arrhythmology (on a model of atrial fibrillation). Vestnik aritmologii. 2011;63:45-54 (in Russian).
49. Streur M, Ratcliffe SJ, Callans D, et al. Atrial fibrillation symptom clusters and associated clinical characteristics and outcomes: A cross-sectional secondary data analysis. Eur J Cardiovasc Nurs. 2018;17(8):707-16. DOI:10.1177/1474515118778445

Д.В. Трошина*1, Д.А. Андреев1, А.В. Фомичева1, А.Н. Воловченко1, Б.А. Волель1,2

1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБНУ «Научный центр психического здоровья», Москва, Россия
*troshina_d_v@staff.sechenov.ru

________________________________________________

Daria V. Troshina*1, Denis A. Andreev1, Anastasia V. Fomicheva1, Alexey N. Volovchenko1, Beatrice A. Volel1,2

1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2 Mental Health Research Center, Moscow, Russia
*troshina_d_v@staff.sechenov.ru